Amarantus Subsidiary MANF
Therapeutics Receives Notice of Allowance from U.S. Patent &
Trademark Office Covering MANF Treatment of Diabetes
- Allowed claims include the treatment of Type 1 and Type 2
Diabetes
Once issued, patents extend exclusivity for MANF in the US into
2032
San Francisco, CA -- December 11, 2017 -- InvestorsHub
NewsWire -- Amarantus Bioscience Holdings, Inc.
(OTCPK:
AMBS), a US-based biotechnology holding company with
subsidiaries developing first-in-class orphan neurologic,
regenerative medicine and ophthalmic therapies, today announced
that its wholly-owned subsidiary MANF Therapeutics, Inc. has
received a notice of allowance from the US Patent & Trademark
Office for a patent application covering the use of mesencephalic
astrocyte-derived neurotrophic factor (MANF) as a treatment for
beta cell disorders, including Type-1 and Type-2 diabetes.
Multiple research groups have published data demonstrating the
therapeutic potential of MANF in treating diabetes, including data
published in the peer-reviewed scientific journal Cell Reports
entitled "MANF Is Indispensable for the
Proliferation and Survival of Pancreatic Cells." That study
demonstrated the therapeutic benefit of MANF in protecting and
restoring pancreatic beta cells in vitro and in vivo in animal
models of diabetes. The study's authors determined "lack of MANF
in vivo in mouse leads to chronic unfolded protein response
(UPR) activation in pancreatic islets. Importantly, MANF protein
enhanced cell proliferation in vitro and overexpression of
MANF in the pancreas of diabetic mice enhanced cell regeneration.
We demonstrate that MANF specifically promotes cell proliferation
and survival, thereby constituting a therapeutic candidate for cell
protection and regeneration."
MANF Therapeutics is preparing to restart IND-enabling
development of MANF in 2018, initially in ophthalmology. There is
strong belief that MANF has significant therapeutic potential
across multiple disease areas, including large indications such as
diabetes and cardiovascular disease.
About Amarantus Bioscience Holdings, Inc.
Amarantus Bioscience Holdings (AMBS)
is a biotechnology company developing treatments and diagnostics
for diseases in the areas of neurology, regenerative medicine and
orphan diseases through its subsidiaries. AMBS' wholly-owned
subsidiary Elto Pharma, Inc. has development rights to
eltoprazine, a Phase 2b-ready small molecule indicated for
Parkinson's disease levodopa-induced dyskinesia, Alzheimer's
aggression and adult ADHD. AMBS acquired the rights to the
Engineered Skin Substitute program (ESS), a regenerative
medicine-based approach for treating severe burns with
full-thickness autologous skin grown in tissue culture that is
being pursued by AMBS' wholly-owned subsidiary Cutanogen
Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics,
Inc. owns key intellectual property rights and licenses from a
number of prominent universities related to the development of the
therapeutic protein known as mesencephalic astrocyte-derived
neurotrophic factor (MANF). MANF Therapeutics, Inc. is
developing MANF-based products as treatments for brain and
ophthalmic disorders. MANF was discovered by the Company's Chief
Scientific Officer John Commissiong, PhD. Dr. Commissiong
discovered MANF from AMBS' proprietary discovery engine PhenoGuard.
AMBS also owns approximately 80 million shares of Avant
Diagnostics, Inc. via the sale of its wholly-owned subsidiary
Amarantus Diagnostics, Inc. that occurred in May 2016.
For further information please visit www.Amarantus.com, or connect with the Amarantus on
Facebook, LinkedIn, Twitter and Google+.
About MANF Therapeutics, Inc.
MANF (mesencephalic-astrocyte-derived neurotrophic factor) is
believed to have broad potential because it is a
naturally-occurring protein produced by the body to reduce/prevent
apoptosis (cell death) in response to injury or disease, via the
unfolded protein response. By administering exogenously produced
MANF the body, Amarantus is seeking to use a regenerative medicine
approach to assist the body with higher quantities of MANF when
needed. Amarantus is the front-runner and primary holder of
intellectual property around MANF, and is initially focusing on the
development of MANF-based protein therapeutics.
MANF's lead indication is retinitis pigmentosa, and additional
indications including Parkinson's disease, diabetes and Wolfram's
syndrome are envisioned. Further applications for MANF may include
Alzheimer's disease, traumatic brain injury, myocardial infarction,
antibiotic-induced ototoxicity and certain other orphan
diseases.
In April 2017, Amarantus incorporated the wholly-owned
subsidiary MANF Therapeutics, Inc. to focus on progressing
preclinical and clinical development of MANF.
Forward-Looking Statements
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believes," "project,"
"expects," "anticipates," "estimates," "intends," "strategy,"
"plan," "may," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ
materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies
is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a
consolidated basis include, but are not limited to: changes in
economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be
considered in evaluating forward-looking statements and undue
reliance should not be placed on such statements.
Amarantus Investor and Media Contact:
Ascendant Partners, LLC
Richard Galterio
+1-732-410-9810
rich@ascendantpartnersllc.com
Source: Amarantus Bioscience Holdings, Inc.